This suggests that stratification of prostate cancer patients based on signature genes characterizing CASP8 T cells could help in selecting patients who would benefit from olaparib treatment, which is a subdivision of personalized treatment for prostate cancer. The gene discussed is CASP8; the disease is prostate carcinoma.